Correlation of Tumor Vascularization Using Spectral Pulse Wave Doppler with Neoadjuvant Chemotherapy Response in IB2 and IIA2 stages of Cervical Cancer

Authors

  • Syamel Muhammad Sub Division of Gynecological Oncology, Obstetrics and Gynecology Department, Faculty of Medicine, Andalas University, Dr. M. Djamil Central General Hospital Padang
  • Nindya Rahmadita Medical Student, Faculty of Medicine, Andalas University, Dr. M. Djamil Central General Hospital Padang

DOI:

https://doi.org/10.25077/aoj.4.2.145-154.2020

Abstract

Cervical cancer is an abnormal growth or cell changes in the cervical wall, which is the 4th rank in the most common cancer among female and the 2nd most common cancer in female aged fifteen until fourty four years old worldwide. Neovascularization becomes an important step in determining the onset and progressive cancer. Neoadjuvant chemotherapy has been evaluated as a treatment strategy in the stages IB2 and IIA2. The use of chemotherapy drug becomes more effective in adjacent and regular vascularization, and it allows the blood flow to the organs more quickly. This study aims to determine the correlation of tumor vascularization using Spectral Pulse Wave Doppler with neoadjuvant chemotherapy response in IB2 and IIA2 stages of cervical cancer. This research is a cohort analytic study which involves thirty six of patient in IB2 and IIA2 stages. The sampling is selected by using consecutive sampling technique. The data includes the result of ultrasound examination and were analyzed by using the Chi-square test. The results of the research on good and poor tumor vascularization had a good response to thirty of patient (83.3%) who were given neoadjuvant chemotherapy. There was no significant effect between tumor vascularization using Spectral Pulse Wave Doppler to the responses of neoadjuvant chemotherapy in IB2 and IIA2 stages of cervical cancer.

Keywords: tumor vascularization using Spectral Pulse Wave Doppler, responses of neoadjuvant chemotherapy, IB2 and IIA2 stages of cervical cancer

References

Bruni L, Barrionuevo-Rosas L, Alberto G, Serrano B, Mena M, Gómez D, et al. Human Papillomavirus and Related Diseases Report. ICO/IARC HPV Information Centre; 2017.

Kementrian Kesehatan RI. Situasi Penyakit Kanker. Riset Kesehatan Dasar. 2015.

Yanti YN. Gambaran Faktor Resiko Kejadian Kanker Serviks di RSUP Dr. M. Djamil Padang. Jurnal Kesehatan Andalas. 2018;3(1):1–17.

Deverakonda A, Gupta N. Diagnosis and treatment of cervical cancer: a review. J Nurs Heal Sci. 2016;2(3):1–11.

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):72–83.

Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant chemotherapy in cervical cancer: An update. Expert Rev Anticancer Ther. 2015;15(10):1171–81.

González-Martín A, González-Cortijo L, Carballo N, Garcia JF, Lapuente F, Rojo A, et al. The current role of neoadjuvant chemotherapy in the management of cervical carcinoma. Gynecol Oncol. 2008;110:36–40.

Sardi JE, Giaroli A, Sananes C, Ferreira M, Soderini A, Bermudez A, et al. Long-Term Follow-up of the First Randomized Trial Using Neoadjuvant Chemotherapy in Stage Ib Squamous Carcinoma of the Cervix : The Final Results. Gynecol Oncol. 1997;67:61–9.

Loizzi V, Vecchio V Del, Crupano FM, Minicucci V, Fumarulo V V, Resta L, et al. A phase II study : dose-dense carboplatin and paclitaxel as neoadjuvant chemotherapy in locally advanced cervical cancer A phase II study : dose-dense carboplatin and paclitaxel as neoadjuvant chemotherapy in locally advanced cervical cancer. J Chemother. 2018;30(4):247–52.

Iwata T, Miyauchi A, Suga Y, Nishio H, Nakamura M, Ohno A, et al. Neoadjuvant chemotherapy for locally advanced cervical cancer. Chinese J Cancer Res. 2016;28(2):235–40.

Alldredge JK, Tewari KS. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer. Oncologist. 2016;21(5):576–85.

Mangla M, Singla D. Transvaginal colour Doppler ultrasound in predicting response to chemoradiation in patients with carcinoma of the cervix. South African J Gynaecol Oncol. 2015;7(2):68–71.

Belitsos P, Papoutsis D, Rodolakis A, Mesogitis S, Antsaklis A. Three-dimensional power Doppler ultrasound for the study of cervical cancer and precancerous lesions. Ultrasound Obstet Gynecol. 2012;40(5):576–81.

Onofrio AD, Gandolfi A. Chemotherapy of vascularised tumours: Role of vessel density and the effect of vascular â€pruningâ€. J Theor Biol. 2010;264(2):253.

Dahlan MS. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. Edisi 3. Vol. 3, Salemba Medika. 2010. 46-60 p.

Qin J, Cheng X, Chen X, Zhang X, Lu W, Xie X. Value of three-dimensional power Doppler to predict clinical and histological response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. Ultrasound Obs Gynecol. 2012;39(1):226–34.

Testa AC, Ferrandina G, Distefano M, Fruscella E, Mansueto D, Basso D, et al. Color Doppler velocimetry and three-dimensional color power angiography of cervical carcinoma. Ultrasound Obstet Gynecol. 2004;24(4):445–52.

Dodampahala SH, Jayakody SN, Gunathilake WCC, Rahubaddha AN, Dodampahala SK. Transvaginal Color Doppler in the Assessment of Cervical Carcinoma and Pre-Cancer : Evidence from a Case Control Study Using Colour Doppler Ultrasonography Pulsatility Index of Uterine Vasculature. Sci Res Publ. 2016;4(3):93–9.

Muhammad S, Suardi D, Tobing MDL. Hubungan gambaran spektral pulse wave doppler dengan respon klinis terapi radiasi eksternal pada kanker serviks stadium IIB-IVA. Maj Kedokt Andalas. 2018;41(1):10–21.

Greco P, Cormio G, Vimercati A, Nacci G, Vagno G Di, Loverro G, et al. Transvarrinal color Doppler ultrasound for monitoring the response to neoadjuvant chemotherapy in advanced cervical cancer. Acta Obstet Gynecol Scand. 1997;76(2):169–72.

Zhu P, Ou Y, Dong Y, Xu P, Yuan L. Expression of VEGF and HIF-1α in locally advanced cervical cancer: potential biomarkers for predicting preoperative radiochemotherapy sensitivity and prognosis. Onco Targets Ther. 2016;9:3031–7.

Chen C-A, Cheng W-F, Lee C-N, Su Y-N, Hsieh C-Y, Hsieh F-J. Power Doppler vascularity index for predicting the response of neoadjuvant chemotherapy in cervical carcinoma. Acta Obstet Gynecol Scand. 2004;83:591–7.

Couvreur K, Naert E, Jaeghere E De, Tummers P, Makar A, Visschere P De, et al. Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates. 2018;1–10.

Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213–9.

Santoso C, Askandar B. Keberhasilan Kemoterapi Neoajuvan Cisplatin-Vincristine-Bleomycin dan Paclitaxel-. Maj Obstet Ginekol. 2011;19(3):1–11.

Fischetti M, Musella A, Di V, Giorgia D. Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer : A Phase II Study. 2015;103–10.

Downloads

Published

2020-07-06

Issue

Vol. 4 No. 2 (2020)

Section

RESEARCH ARTICLE

License

Copyright (c) 2020 JOURNAL OBGIN EMAS

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

Authors who publish with this journal agree to the following terms:

  1. Authors retain the copyright of published articles and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

License:

Andalas Obstetrics and Gynecology Journal (AOJ) is published under the terms of the Creative Commons Attribution 4.0 International License. This license permits anyone to copy and redistribute this material in any form or format, compose, modify, and make derivatives of this material for any purpose, including commercial purposes, as long as they credit the author for the original work.